Form 8-K - Current report:
SEC Accession No. 0001641172-25-017810
Filing Date
2025-07-03
Accepted
2025-07-03 16:10:52
Documents
14
Period of Report
2025-07-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 45236
2 EX-1.1 ex1-1.htm EX-1.1 305912
3 EX-5.1 ex5-1.htm EX-5.1 10481
  Complete submission text file 0001641172-25-017810.txt   601042

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ltrn-20250703.xsd EX-101.SCH 3029
5 XBRL LABEL FILE ltrn-20250703_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE ltrn-20250703_pre.xml EX-101.PRE 22368
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3793
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39318 | Film No.: 251105656
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)